{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000007","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.558409+00:00","generated_at":"2026-05-28T01:52:08.169410+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen announces positive Phase 2A results for PH284 in cancer cachexia; 71% hunger improvement","bullets":["PH284 nasal spray demonstrated 71% improvement in subjective feeling of hunger before dinner on Day 7 vs <1% for placebo.","No serious adverse events; adverse events similar to placebo and attributed to underlying cancer, not treatment.","PH284 is fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal.","Study enrolled 40 female patients with cachexia due to terminal cancer; double-blind, placebo-controlled design."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000007","json":"https://secwatch.observer/filing/0001411685-25-000007.json","markdown":"https://secwatch.observer/filing/0001411685-25-000007.md","text":"https://secwatch.observer/filing/0001411685-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000007/0001411685-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000007/vtgn-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:52:08.169410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}